Skip to main content

Table 4 Weibull survival model with random effects in 2131 children on antiretroviral therapy (ART).

From: 12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000-2008

 

Univariate analysis

Multivariate analysis

 

HR*

95% CI

P

aHR

95% CI

P

Sex

      

   Boys

1

-

-

1

-

-

   Girls

1.1

0.7-1.5

0.72

1.0

0.7-1.4

0.88

Age at ART initiation

      

   10 years and plus

1

-

-

1

-

-

   [5-10] years

0.8

0.5-1.4

0.49

0.9

0.5-1.5

0.70

   [3-5] years

0.6

0.3-1.2

0.15

0.9

0.5-1.7

0.68

   [1-3] years

1.5

0.9-2.6

0.12

1.2

0.7-2.1

0.40

   < 12 months

1.2

0.4-4.3

0.69

1.1

0.3-3.8

0.79

ART regimen at baseline

      

   2 NRTI+1 NNRTI

1

-

-

1

  

   2 NRTI+1 PI

0.7

0.4-1.0

0.06

0.9

0.6-1.5

0.76

   Other

0.2

0.02-2.6

0.21

1.0

0.2-5.0

0.98

Clinical stage at ART initiation

      

   A, B or I, II, III

1

-

-

1

-

-

   AIDS or IV

6.0

3.9-9.2

< 0.01

2.5

1.6-3.9

< 0.01

   Unknown

0.9

0.4-2.0

0.90

1.4

0.7-2.9

0.29

% CD4 at ART initiation

      

   ≥ 15%

1

-

-

1

-

-

   < 15%

2.1

1.1-3.9

0.02

2.1

1.1-4.1

0.03

   Missing

1.5

0.7-3.3

0.22

1.5

0.6-3.6

0.27

Year of ART initiation

      

   ≤ 2004

1

-

-

1

-

-

   2005

1.8

1.0-3.0

0.03

1.7

1.0-2.9

0.04

   ≥ 2006

2.6

1.7-4.2

< 0.01

2.8

1.7-4.7

< 0.01

Initiation of cotrimoxazole at ART initiation

      

   No

1

-

-

1

-

-

   Yes

1.3

0.7-2.5

0.39

0.9

0.5-1.7

0.67

   Missing

0.6

0.1-3.1

0.50

0.4

0.1-2.3

0.30

  1. IeDEA paediatric West Africa database (pWADA), 2000-2007. Mortality analysis.
  2. *HR = Hazard Ratio, **95% CI = 95% Confidence Interval, aHR = adjusted Hazard Ratio
  3. Heterogeneity between cohort, p = 0.25